Cidara Therapeutics Announces Divestiture of Rezafungin to Mundipharma* to Focus on Advancing the Clinical Development of Cloudbreak DFC Pipeline
Mundipharma合作协议 - 公司与Mundipharma签订资产购买协议，将rezafungin的商业权利转让给Mundipharma，预计可节省约1.28亿美元成本[1] - Mundipharma将承担ReSPECT Phase 3临床试验的进行和资金支持，以及rezafungin专利组合的成本和CMC和监管义务[2] - Mundipharma将获得所有未来来自Mundipharma和Melinta Therapeutics的未来版税和里程碑，以及rezafungin的知识产权、产品数据、监管批准等[3]